BTIG Maintains Buy on Castle Biosciences, Lowers Price Target to $40
Castle Biosciences
Castle Biosciences CSTL | 0.00 |
BTIG analyst Mark Massaro maintains Castle Biosciences (NASDAQ:
CSTL) with a Buy and lowers the price target from $50 to $40.
